# CorMedix Inc. (CRMD)

Informational only - not investment advice.

CIK: 0001410098
SIC: 2834 Pharmaceutical Preparations
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2834 Pharmaceutical Preparations](/industry/2834/)
Latest 10-K filed: 2026-03-05
SEC page: https://www.sec.gov/edgar/browse/?CIK=1410098
Filing source: https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 311709000 | USD | 2025 | 2026-03-05 |
| Net income | 163055000 | USD | 2025 | 2026-03-05 |
| Assets | 826142000 | USD | 2025 | 2026-03-05 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001410098.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 210,130 | 224,105 | 329,327 | 429,797 | 283,266 | 239,231 | 190,936 | 65,408 |  | 43,472,000 | 311,709,000 |
| Net income |  | -24,643,627 | -33,009,914 | -26,829,630 | -16,433,074 | -22,027,683 | -28,210,226 | -29,701,705 | -46,339,227 | -17,930,000 | 163,055,000 |
| Operating income |  | -24,760,918 | -32,924,110 | -26,864,196 | -21,007,876 | -27,220,752 | -29,437,585 | -30,623,968 | -48,957,788 | -22,356,000 | 150,141,000 |
| Gross profit | -108,588 | -142,568 | 214,363 | 33,011 | -89,968 | 34,385 | 41,998 | 61,674 |  | 40,282,000 | 275,748,000 |
| Diluted EPS |  |  |  |  |  |  | -0.75 | -0.74 | -0.91 | -0.30 | 2.04 |
| Operating cash flow |  | -22,265,395 | -28,587,180 | -23,700,565 | -15,052,024 | -21,967,638 | -21,155,223 | -24,356,732 | -38,409,480 | -50,615,000 | 175,046,000 |
| Capital expenditures |  | 58,723 | 151,988 | 48,893 | 36,571 | 112,638 | 1,425,329 | 219,360 | 327,300 | 116,000 | 2,260,000 |
| Assets |  | 21,906,386 | 13,453,933 | 18,825,914 | 29,475,910 | 49,308,303 | 68,945,576 | 62,038,259 | 82,059,957 | 118,846,000 | 826,142,000 |
| Liabilities |  | 4,091,860 | 6,260,582 | 13,891,658 | 5,829,650 | 5,085,291 | 6,147,509 | 6,978,523 | 11,917,528 | 34,189,000 | 420,835,000 |
| Stockholders' equity |  | 17,814,526 | 7,193,351 | 4,934,255 | 23,646,260 | 44,223,012 | 62,798,067 | 55,059,736 | 70,142,000 | 84,657,000 | 405,307,000 |
| Cash and cash equivalents |  | 8,064,490 | 10,379,729 | 17,623,770 | 16,350,237 | 41,905,469 | 53,317,405 | 43,148,323 | 43,642,684 | 40,651,000 | 144,837,000 |
| Free cash flow |  | -22,324,118 | -28,739,168 | -23,749,458 | -15,088,595 | -22,080,276 | -22,580,552 | -24,576,092 | -38,736,780 | -50,731,000 | 172,786,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  |  |  |  |  | -41.24% | 52.31% |
| Operating margin |  |  |  |  |  |  |  |  |  | -51.43% | 48.17% |
| Return on equity |  | -138.33% | -458.89% |  | -69.50% | -49.81% | -44.92% | -53.94% | -66.06% | -21.18% | 40.23% |
| Return on assets |  | -112.50% |  | -142.51% | -55.75% | -44.67% | -40.92% | -47.88% | -56.47% | -15.09% | 19.74% |
| Liabilities / equity |  | 0.23 | 0.87 | 2.82 | 0.25 | 0.11 | 0.10 | 0.13 | 0.17 | 0.40 | 1.04 |
| Current ratio |  | 5.34 | 2.12 | 2.40 | 5.04 | 11.58 | 12.44 | 9.44 | 6.97 | 3.39 | 2.11 |

## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-14. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001410098.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q2 | 2022-06-30 |  |  | -0.19 | reported discrete quarter |
| 2022-Q3 | 2022-09-30 |  |  | -0.17 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.24 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  | -11,273,618 | -0.25 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 |  | -9,744,354 | -0.17 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 |  | -14,754,029 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 |  | -14,466,123 | -0.25 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 |  | -14,151,489 | -0.25 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 |  | -2,776,812 | -0.05 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 |  | 13,464,404 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 |  | 20,643,898 | 0.30 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 |  | 19,827,981 | 0.28 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 |  | 108,562,980 | 1.26 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 |  | 14,020,141 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 127,427,000 | 38,601,000 | 0.43 | reported discrete quarter |

## Macro Cross-References
- [CPIAUCSL](/indicator/CPIAUCSL/): Consumer Price Index for All Urban Consumers: All Items in U.S. City Average
- [UNRATE](/indicator/UNRATE/): Unemployment Rate
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [DFEDTARU](/indicator/DFEDTARU/): Federal Funds Target Range - Upper Limit
- [DFEDTARL](/indicator/DFEDTARL/): Federal Funds Target Range - Lower Limit
- [DGS3MO](/indicator/DGS3MO/): Market Yield on U.S. Treasury Securities at 3-Month Constant Maturity
- [DGS2](/indicator/DGS2/): Market Yield on U.S. Treasury Securities at 2-Year Constant Maturity
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [DGS30](/indicator/DGS30/): Market Yield on U.S. Treasury Securities at 30-Year Constant Maturity
- [T10Y2Y](/indicator/T10Y2Y/): 10-Year Treasury Constant Maturity Minus 2-Year Treasury Constant Maturity
- [CPILFESL](/indicator/CPILFESL/): Consumer Price Index for All Urban Consumers: All Items Less Food and Energy
- [CPIUFDSL](/indicator/CPIUFDSL/): Consumer Price Index for All Urban Consumers: Food
- [CPIENGSL](/indicator/CPIENGSL/): Consumer Price Index for All Urban Consumers: Energy
- [CUSR0000SAH1](/indicator/CUSR0000SAH1/): Consumer Price Index for All Urban Consumers: Shelter
- [PCEPI](/indicator/PCEPI/): Personal Consumption Expenditures: Chain-type Price Index
- [PCEPILFE](/indicator/PCEPILFE/): Personal Consumption Expenditures Excluding Food and Energy: Chain-type Price Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [T10YIE](/indicator/T10YIE/): 10-Year Breakeven Inflation Rate
- [U6RATE](/indicator/U6RATE/): Total Unemployed, Plus All Marginally Attached Workers Plus Total Employed Part Time for Economic Reasons
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CIVPART](/indicator/CIVPART/): Labor Force Participation Rate
- [EMRATIO](/indicator/EMRATIO/): Employment-Population Ratio
- [UNEMPLOY](/indicator/UNEMPLOY/): Unemployed
- [CE16OV](/indicator/CE16OV/): Employment Level
- [ICSA](/indicator/ICSA/): Initial Claims
- [JTSJOL](/indicator/JTSJOL/): Job Openings: Total Nonfarm
- [JTSQUR](/indicator/JTSQUR/): Quits: Total Nonfarm
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [A191RL1Q225SBEA](/indicator/A191RL1Q225SBEA/): Real Gross Domestic Product: Percent Change from Preceding Period
- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [HOUST](/indicator/HOUST/): New Privately-Owned Housing Units Started: Total Units
- [PERMIT](/indicator/PERMIT/): New Privately-Owned Housing Units Authorized in Permit-Issuing Places: Total Units
- [RSAFS](/indicator/RSAFS/): Advance Retail Sales: Retail Trade
- [PCE](/indicator/PCE/): Personal Consumption Expenditures
- [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income
- [PSAVERT](/indicator/PSAVERT/): Personal Saving Rate
- [M2SL](/indicator/M2SL/): M2
- [BOPGSTB](/indicator/BOPGSTB/): U.S. International Trade in Goods and Services: Balance
- [MSPUS](/indicator/MSPUS/): Median Sales Price of Houses Sold for the United States
- [HSN1F](/indicator/HSN1F/): New One Family Houses Sold: United States
- [RHORUSQ156N](/indicator/RHORUSQ156N/): Homeownership Rate in the United States
- [TTLCONS](/indicator/TTLCONS/): Total Construction Spending: Total Construction in the United States
- [RRVRUSQ156N](/indicator/RRVRUSQ156N/): Rental Vacancy Rate in the United States
- [TOTALSL](/indicator/TOTALSL/): Total Consumer Credit Owned and Securitized
- [REVOLSL](/indicator/REVOLSL/): Revolving Consumer Credit Owned and Securitized
- [DRCCLACBS](/indicator/DRCCLACBS/): Delinquency Rate on Credit Card Loans, All Commercial Banks
- [GDP](/indicator/GDP/): Gross Domestic Product
- [GPDI](/indicator/GPDI/): Gross Private Domestic Investment
- [GCE](/indicator/GCE/): Government Consumption Expenditures and Gross Investment
- [PCEC](/indicator/PCEC/): Personal Consumption Expenditures
- [NETEXP](/indicator/NETEXP/): Net Exports of Goods and Services
- [GFDEBTN](/indicator/GFDEBTN/): Federal Debt: Total Public Debt
- [GFDEGDQ188S](/indicator/GFDEGDQ188S/): Federal Debt: Total Public Debt as Percent of Gross Domestic Product
- [FYFSD](/indicator/FYFSD/): Federal Surplus or Deficit
- [FGRECPT](/indicator/FGRECPT/): Federal Government Current Receipts
- [FGEXPND](/indicator/FGEXPND/): Federal Government: Current Expenditures
- [MANEMP](/indicator/MANEMP/): All Employees, Manufacturing
- [USCONS](/indicator/USCONS/): All Employees, Construction
- [USTRADE](/indicator/USTRADE/): All Employees, Retail Trade
- [USFIRE](/indicator/USFIRE/): All Employees, Financial Activities
- [USGOVT](/indicator/USGOVT/): All Employees, Government
- [AWHAETP](/indicator/AWHAETP/): Average Weekly Hours of All Employees, Total Private
- [DGORDER](/indicator/DGORDER/): Manufacturers' New Orders: Durable Goods
- [NEWORDER](/indicator/NEWORDER/): Manufacturers' New Orders: Nondefense Capital Goods Excluding Aircraft
- [BUSINV](/indicator/BUSINV/): Total Business Inventories
- [EXPGS](/indicator/EXPGS/): Exports of Goods and Services
- [IMPGS](/indicator/IMPGS/): Imports of Goods and Services
- [IR](/indicator/IR/): Import Price Index (End Use): All Commodities
- [PPIFIS](/indicator/PPIFIS/): Producer Price Index by Commodity: Final Demand

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1410098/000141009826000021/crmd-20260331.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-05-14
Report date: 2026-03-31

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and our audited 2025 Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”), on March 5, 2026.

Forward Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties. Actual outcomes or results may differ from anticipated results, sometimes materially. Factors that could cause actual results to differ include, but are not limited to: the ability of the combined company to achieve the identified synergies; the ability to integrate the Melinta business into CorMedix and realize the anticipated strategic benefits of the transaction within the expected time-frames or at all; that such integration may be more difficult, time-consuming or costly than expected; that operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers or suppliers) may be greater than expected following the closing of the transaction; the expected benefits and success of Melinta’s products and product candidates; potential litigation relating to the transaction that could be instituted against CorMedix or its directors; rating agency actions and CorMedix’s ability to access short- and long-term debt markets on a timely and affordable basis; general economic conditions that are less favorable than expected; geopolitical developments and additional changes in international trade policies and relations, including tariffs; and the ability of our products and product candidates to compete effectively against current and future competitors.

Overview

CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as “we,” “us,” “our” or the “Company”) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our results of operations are driven by the commercialization of DefenCath® in the United States and, following the acquisition of Melinta in August 2025 (the "merger"), a diversified portfolio of hospital- and clinic-focused infectious disease products. The financial results of Melinta have been included in our consolidated financial statements since the acquisition date, and, as a result, comparisons to prior periods may not be meaningful.

There have been no material changes to our business, strategy or key drivers of our results of operations from those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Accordingly, this discussion should be read in conjunction with the information presented in the Form 10-K, including Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Our operating results continue to be influenced by a number of factors, including product adoption and utilization trends, pricing and reimbursement dynamics, including those applicable to DefenCath, and the ongoing integration and performance of the Melinta portfolio. In addition, our results reflect the impact of our capital structure, including interest expense associated with our convertible senior notes, as well as investments in our commercial infrastructure and development activities.

23

Table of Contents

We continue to focus on executing our commercial strategy, supporting product adoption across our portfolio, and advancing initiatives designed to optimize our operating model, improve efficiency within the broader organization, and support long-term growth. While our strategy and key drivers remain unchanged, our results may continue to be affected by the timing and pace of product adoption, reimbursement dynamics, and the execution of cost optimization initiatives.

Recent Developments

REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults. On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation, and if approved by the FDA, it is targeting commercialization of REZZAYO in this second indication beginning in 2027.

On April 2, 2026, the U.S. government issued an executive order imposing new tariffs on certain imported goods, including active pharmaceutical ingredients (“APIs”), excipients, and packaging materials commonly used in the pharmaceutical industry. The Company is currently assessing the impact of the tariffs, which may adversely affect our gross margins and operating results. We are currently in the process of onshoring the manufacture of a number of products into the U.S., which we believe will both drive lower manufacturing costs and mitigate certain incremental costs related to tariffs. However, there can be no assurance that we will be able to fully or substantially offset these incremental costs.

Results of Operations

Our results of operations are primarily driven by product sales across our portfolio, including contributions from the Melinta acquisition and continued momentum of DefenCath. Operating expenses reflect investments in commercialization, integration activities and personnel to support the expanded business. In addition, our results are impacted by our capital structure, including interest expense associated with our convertible senior notes. Period-to-period comparisons are affected by the inclusion of Melinta's results of operations beginning on August 29, 2025, in connection with the merger.

On July 1, 2026, DefenCath’s TDAPA reimbursement transitions into a post-TDAPA Add-On Adjustment, the calculation of which is determined by CMS. As a result of the methodology utilized by CMS, the level of reimbursement provided to institutions treating dialysis patients will significantly decline, and as a result, CorMedix expects a corresponding reduction to its net pricing for DefenCath in the second half of 2026. We currently estimate, based on the known CMS methodology for calculation of the post TDAPA Add-on, that the 2027 payment could increase meaningfully above the payment rate for the second half of 2026.

24

Table of Contents

Comparison of the Three Months Ended March 31, 2026 and 2025.

The following is a tabular presentation of our unaudited consolidated operating results for the three months ended March 31, 2026 and 2025 (in thousands):

For the Three Months Ended

March 31,

% Increase/ (Decrease)

2026

2025

Revenue:

Product sales, net

$

121,916 

$

39,082 

212 

%

Contract revenue

5,511 

- 

100 

%

Total Revenues

127,427 

39,082 

226 

%

Cost of sales (exclusive of amortization of intangibles)

12,005 

1,545 

677 

%

Amortization of intangibles

10,300 

52 

19,708 

%

Gross profit

105,122 

37,485 

180 

%

Operating Expenses:

Research and development

7,212 

3,193 

126 

%

Selling and marketing

12,532 

4,474 

180 

%

General and administrative

21,720 

9,693 

124 

%

Total Operating Expenses

41,464 

17,360 

139 

%

Income From Operations

63,658 

20,125 

216 

%

Other (Expense) Income:

Unrealized loss on marketable security

(3,546)

- 

100 

%

Change in contingent consideration

(4,199)

- 

100 

%

Other non-operating (expense) income, net

(268)

519 

(152)

%

Total Other (Expense) Income

(8,013)

519 

(1,644)

%

Income before income taxes

55,645 

20,644 

170 

%

Tax expense

17,044 

- 

100 

%

Net Income

$

38,601 

$

20,644 

87 

%

Revenue for the three months ended March 31, 2026 was $127.4 million as compared to $39.1 million for the same period in 2025, an increase of $88.3 million or 226%. The increase is due to the inclusion of the Melinta Portfolio in the three months ended March 31, 2026 as well as strong first quarter execution and positive underlying demand trends.

For the three months ended March 31, 2026 and 2025, Product Sales were $121.9 million and $39.1 million, respectively, representing an increase of $82.8 million or 212%. The increase is primarily due to sustained DefenCath demand, including with the onboarding of our large dialysis customer mid-last year, along with the addition of Melinta revenue. Product Sales during the periods consist primarily of sales of DefenCath and reflects the shipment of DefenCath to direct customers and specialty distributors, net of estimates for applicable variable consideration, which consists primarily of distribution service fees, prompt pay and other discounts, product returns, chargebacks, rebates and volume incentive rebates, shelf-stock adjustments and data fees, and includes a change in accounting estimate for Medicaid and returns' sales allowances of $9.0 million during the three months ended March 31, 2026. Revenue from the Melinta Portfolio represents $24.4 million of product sales in the first quarter of 2026, reflecting typical first quarter purchasing patterns for the Melinta Portfolio, including the impact of lower wholesaler channel inventory levels at the end of the first quarter of 2026 relative to the fourth quarter of 2025.

Contract Revenue reflects $2.4 million earned under the BARDA agreement and $3.1 million related to milestone, royalty, and inventory revenue under Melinta’s licensing agreements.

25

Table of Contents

The following is a summary of our Total Revenue between the DefenCath sales and the contribution from the Melinta Portfolio (in thousands):

Three Months Ended

March 31,

2026

2025

Product Sales:

DefenCath

$

97,511 

$

39,082 

Melinta Portfolio

24,405 

- 

Total product sales

121,916 

39,082 

Contract Revenue

5,511 

- 

Total Revenue

$

127,427 

$

39,082 

Cost of Sales for the three months ended March 31, 2026 was $12.0 million as compared to $1.5 million for the same period in 2025, an increase of $10.5 million, or 677%. Cost of revenues include direct and indirect costs related to the manufacturing and

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high

Item 7. Management’s Discussion and Analysis of Financial
Condition and Results of Operations

You should read the following
discussion and analysis together with our audited consolidated financial statements and the accompanying notes contained elsewhere in
this report. This discussion contains forward-looking statements, within the meaning of Section 27A of Securities Act, Section 21E of
the Exchange Act, and the Private Securities Litigation Reform Act of 1995, including statements regarding our expected financial
condition, business and financing plans. These statements involve risks and uncertainties. Our actual results could differ materially
from the results described in or implied by these forward-looking statements as a result of various factors, including those discussed
below and elsewhere in this Annual Report on Form 10-K, particularly under the heading “Risk Factors.”

Overview

The Company is a biopharmaceutical
company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions.

Our primary focus has been
commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name
DefenCath is the U.S. proprietary name approved by the U.S. FDA.

DefenCath is an FDA
approved antimicrobial CLS (a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL) indicated to reduce the
incidence of CRBSI in adult patients with kidney failure receiving chronic hemodialysis through a CVC It is indicated for use in a
limited and specific population of patients. CRBSIs can lead to treatment delays and increased costs to the healthcare system when
they occur due to extended and often repeat hospitalizations, need for IV antibiotic treatment, long-term anticoagulation therapy,
removal/replacement of the CVC, related treatment costs, as well as increased mortality. DefenCath is the first and only
FDA-approved antimicrobial CLS in the U.S. and was shown to reduce the risk of CRBSI by up to 71% in a Phase 3 clinical study.

33

DefenCath is subject to Medicare
ESRD PPS, which provides bundled payment for renal dialysis services and affords a TDAPA, which provides temporary, additional payments
for certain new drugs and biologicals. TDAPA reimbursement is calculated based on 100 percent ASP (or 100 percent of wholesale acquisition
price or manufacturers’ list price, respectively, if such data is unavailable). TDAPA and post-TDAPA add-on payment adjustments
for DefenCath apply for five years (with such add-on payments applying to all ESRD PPS payments for years three through five). DefenCath’s
TDAPA began on July 1, 2024.

Looking forward, on July 1,
2026, DefenCath’s TDAPA reimbursement transitions into a three-year, post-TDAPA Add-On Payment phase, the calculation of which is
determined and published by CMS and will be $2.37 for the third and fourth quarters of 2026. As a result of the methodology utilized by
CMS, the level of reimbursement provided to institutions treating dialysis patients will significantly decline, and as a result, we expect
a corresponding reduction to net pricing for DefenCath in the third and fourth quarters of 2026. If CMS utilizes the same methodology
to calculate the 2027 post-TDAPA Add-On Adjustment, which will be effective on January 1, 2027, we estimate the value of the Add-On Adjustment
will be three to five-times higher than that granted for the third and fourth quarters of 2026, which we expect may result in higher DefenCath
sales prices in 2027 relative to the second half 2026. After January 1, 2027, the post-TDAPA Add-On Payment will be reassessed again and
be made effective on January 1, 2028 and January 1, 2029, covering the three-year period through June 30, 2029.

Acquisition of Melinta

 On August 29, 2025 (the “Closing Date”),
we completed the acquisition of Melinta. The acquisition of Melinta expanded our team, commercial platform and increased the commercial
portfolio with six marketed, hospital- and clinic-focused infectious disease products, comprised of REZZAYO® (rezafungin for injection),
MINOCIN® (minocycline) for Injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin),
BAXDELA® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL® (metoprolol succinate) (together,
the Melinta Portfolio. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing
Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation.
The completion of the Phase III study for REZZAYO is expected in 2026.

The financial results of Melinta are included in
our consolidated financial statements starting on August 29, 2025. Melinta’s financial results were not reflected in reported figures
in the periods preceding the Closing Date. As a result, the reported results for 2025 and 2024 are not comparable. To assist with the
discussion of 2025 and 2024 results on a comparable basis and provide more meaningful discussion, certain pro forma historical results
are included in Note 3 to the Consolidated Financial Statements included herein. This information does not purport to reflect what our
financial and operational results would have been had the acquisition been consummated at the beginning of the periods presented. In addition,
further information relating to the acquisition of Melinta is included in Note 3 to the Consolidated Financial Statements included herein.

Pursuant to the terms of the
Merger Agreement, we acquired Melinta via a merger in which Merger Sub merged with and into Melinta, with Melinta surviving as a wholly-owned
subsidiary of the Company. In consideration for the Merger, we (i) paid to the former Melinta equity holders an aggregate of $260.0 million
in cash, subject to adjustment for estimated Company Cash and estimated Working Capital as compared to the Working Capital Target (each
as defined in the Merger Agreement), and (ii) issued to certain of the former Melinta equity holders an aggregate of 3.3 million common
shares of the Company (the “Merger Shares”). In addition, in connection with the Merger, we paid $23.2 million to acquire
the Toprol XL product rights, which Melinta had licensed from a third party. The total cash consideration was funded by a combination
of the Company’s existing cash on hand and net proceeds from the Company’s $150.0 million aggregate principal amount of convertible
senior notes due 2030 (as described below).

Additionally, former Melinta
equity holders are eligible to receive certain contingent payments pursuant to the terms of the Merger Agreement and the Contingent Payment
Agreement, which provides for milestone and net sales-based payments. Upon the issuance of the FDA marketing approval of REZZAYO (or any
product that contains the active ingredient rezafungin), for the prevention or prophylaxis of invasive fungal infections in adult patients
undergoing allogeneic stem cell blood and marrow transplant or the regulatory equivalent on or prior to June 30, 2029, we shall pay, in
cash or common shares, par value $0.001 per share, of the Company at the Company’s election, to the former Melinta equity holders
the following payments:

(i)

if the FDA-approved labeling includes candida, $20 million;

(ii)

if the FDA-approved labeling includes aspergillus, $2.5 million;
and

(iii)

if the FDA-approved labeling includes pneumocystis, $2.5 million.

Further, the Contingent Payment Agreement provides
that we will pay to the former Melinta equity holders tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN®
U.S. net sales.

Additionally, on the Closing
Date, the Company and the consenting Melinta members entered into a registration rights agreement (the “Registration Rights Agreement”),
pursuant to which, among other things, the Company agreed to register for resale, pursuant to Rule 415 under the Securities Act, the Merger
Shares, pursuant to the Contingent Payment Agreement.

34

Convertible Notes Offering

On August 6, 2025, the Company entered into subscription
agreements with certain investors to provide for the issuance of $150.0 million aggregate principal amount of its convertible senior notes
due 2030 (the “Notes”) in a private placement, exempt from registration pursuant to Section 4(a)(2) of the Securities Act.
The Notes were issued on August 12, 2025 and are eligible for resale to persons reasonably believed to be qualified institutional buyers
pursuant to Rule 144A of the Securities Act.

The Notes are governed by an Indenture, by and
between the Company and U.S. Bank Trust Company, National Association, as trustee. The Notes bear interest at a rate of 4.00% per annum,
payable semi-annually in arrears on February 1 and August 1 of each year, commencing on February 1, 2026. The Notes will mature on August
1, 2030 and are senior, unsecured obligations of the Company.

The Company used the net proceeds of the issuance
of the Notes to fund a portion of the purchase price payable in connection with the Merger, including related fees and expenses. See Note
7 to the Consolidated Financial Statements for further information regarding the Notes.

Follow-On Offering

In addition, on June 30, 2025, the Company completed
an underwritten public offering of common stock pursuant to the Company’s universal shelf registration statement on Form S-3, selling
an aggregate of 6,604,507 shares, at the price of $12.87 per share less an underwriting discount of $0.229 per share (the “Follow-On
Offering”). The Company received aggregate net proceeds of approximately $82.4 million after deducting the underwriting discounts
and commissions and offering expenses payable by the Company. See Note 10 to the Consolidated Financial Statements for further information
regarding the Follow-On Offering.

Financial Operations Overview

Revenue from Product Sales

We generate product revenue
from commercial sales of DefenCath to a limited number of direct customers as well as distributors and, from the Closing Date, we generate
revenue from sales of the Melinta Portfolio. We recognize revenue from the sale of our Products when our direct customers obtain control
of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts,
returns, rebates, shelf-stock adjustments and data fees. Actual amounts of consideration ultimately received may differ from our estimates.
If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and
earnings in the period such estimates are adjusted.

We continue to assess our
estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.

Contract Revenue

As a result of the Merger,
we recognize revenue associated with Melinta’s license and collaboration agreements for the research and development and/or commercialization
of its therapeutic products in the form of licensing fees, milestone payments, royalties on sales in our partners’ respective licensed
territories, and sale of product inventory.

In addition, Melinta holds
a partnership with BARDA, a government agency, to advance BAXDELA and VABOMERE for use in pediatrics and to partner on the development
of BAXDELA against certain biothreat pathogens. Research and development services under the contract are recognized as contract revenue
over time, as the performance obligation is satisfied, in accordance with the BARDA agreement. Under this contract, BARDA has awarded
a total of $47.5 million with the potential of additional funding of $97.1 million, amounting to total funding up to $144.6 million, if
all options are exercised. If all contract options are exercised, the contract is expected to continue through 2034.

35

Cost of Revenues

Cost of revenues include
direct and indirect costs related to the manufacturing and distribution of our Products, including product cost, packaging services,
freight, and an allocation of overhead costs that are primarily fixed such as salaries, benefits and insurance. In addition, cost of
revenues includes the amortization of intangible assets primarily associated with the fair value of the products acquired in the Melinta
Portfolio that were recorded as a result of the Merger (see Note 3 to the Consolidated Financial Statements included herein).

Research and Development Expense

Research and development (“R&D”)
expense consists of: (i) internal costs associated with our development activities; (ii) payments we make to third-party contract research
organizations, contract manufacturers, investigative sites, and consultants; (iii) technology and intellectual property license costs;
(iv) manufacturing development costs; (v) personnel related expenses, including salaries, stock–based compensation expense, benefits,
travel and related costs for the personnel involved in drug development; and (vi) activities relating to regulatory filings and pre-clinical
studies and clinical trials. All R&D is expensed as incurred.

The process of conducting
pre-clinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success
for each product line and clinical trial may be affected by a variety of factors, including, among others, the quality of the product
line’s early clinical data, investment in the program, competition, manufacturing capabilities and commercial viability. As a result
of the uncertainties associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine
the duration and completion costs of future clinical stages of our product lines or when, or to what extent, we will generate revenues
from the commercialization and sale of any of our future product lines.

Development timelines, probability
of success and development costs vary widely. We are currently focused on the commercialization of our Products in the United States.

Selling and Marketing Expense

Selling and marketing (“S&M”)
expense includes the cost of salaries and related costs for personnel in sales and marketing including our contract sales force, brand
building, advocacy, market research and consulting costs. Selling and marketing expenses are expensed as incurred.

General and Administrative Expense

General and administrative
(“G&A”) expenses consist principally of salaries and related costs for personnel in executive, finance and administrative
functions including payroll taxes and health insurance, stock-based compensation and travel expenses. Other general and administrative
expenses include merger-related costs, facility-related costs, insurance and professional fees for legal, patent review, consulting, and
accounting services. General and administrative expenses are expensed as incurred. 

Interest Income

Interest income consists of
interest earned on our cash and cash equivalents and short-term investments.

Foreign Currency Exchange Transaction Gain
(Loss)

Foreign currency exchange
transaction gain (loss) is the result of re-measuring transactions denominated in a currency other than our functional currency and is
reported in the consolidated statement of operations as a separate line item within other income (expense).

Unrealized Gains on Marketable Security

Unrealized gains on marketable
security represents the change in fair market value of our marketable equity securities.

36

Change in Contingent Consideration

Change in contingent consideration
represents the change in fair market value of the contingent consideration liabilities in connection with the Merger. Contingent consideration
in connection with the business combination is initially measured at fair value at the acquisition date and classified as a liability
and subsequently remeasured at fair value at each reporting date using a probability-weighted discounted cash flow model, or Monte Carlo
simulation, based on significant inputs. Changes in fair value are recognized as change in contingent
consideration within other expenses in the consolidated statement of operations.

Interest Expense

Interest expense consists
primarily of interest incurred on the Notes.

Tax Expense / Benefit

Income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax
bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in operating results in the period that includes the enactment date.
Management assesses the realizability of deferred tax assets and records a valuation allowance if it is more likely than not that all
or a portion of the deferred tax assets will not be realized.

Results of Operations

Comparison of the Years Ended December 31, 2025 and 2024

The following is a tabular
presentation of our audited consolidated operating results for the years ended December 31, 2025 and 2024 (in thousands): Results
for 2025 are inclusive of Melinta’s operations from the acquisition date of August 29, 2025 through December 31, 2025, while the
prior period does not include combined results. The below discussion of changes to our revenue and expenses compared to the prior year
largely focus on material factors independent of the acquisition.

2025

2024

Net of

Change

Increase

(Decrease)

Revenue

$

304,344

$

43,472

600

%

Contract Revenue

7,365

-

100

%

Total Revenue

311,709

43,472

617

%

Cost of sales

22,089

3,034

628

%

Intangible Amortization

13,872

156

8,792

%

Gross profit (loss)

275,748

40,282

585

%

Operating Expenses:

Research and development

19,333

3,942

390

%

Selling and marketing

38,054

28,737

32

%

General and administrative

68,220

29,959

128

%

Total operating expenses

125,607

62,638

101

%

Income (loss) from operations

150,141

(22,356

)

(772

)%

Interest income

3,846

2,579

49

%

Foreign exchange transaction loss   

(52

)

(31

)

68

%

Unrealized gain on marketable security

5,364

-

100

%

Other Income

-

519

(100

)%

Change in contingent consideration

(6,501

)

-

100

%

Interest expense

(2,782

)

(36

)

7,628

%

Total other income (expenses)

(125

)

3,031

(104

)%

Income (loss) before income taxes

150,016

(19,325

)

(876

)%

Tax (benefit)

(13,039

)

(1,395

)

835

%

Net income (loss)

163,055

(17,930

)

(1,009

)%

Other comprehensive (loss) income

(88

)

(3

)

2,833

%

Comprehensive income (loss)

$

162,967

$

(17,933

)

(1,009

)%

37

Revenue. Revenue for
the year ended December 31, 2025 was $311.7 million as compared to $43.5 million for the same period in 2024, an increase of $268.2 million,
or 617%.

For the years ended December
31, 2025 and 2024, product sales were $304.3 million and $43.5 million, respectively, representing an increase of $260.8 million, or 600%.
Product sales during fiscal year 2024 and 2025 consist primarily of sales of DefenCath, which was approved by the FDA in November 2023
and launched in the U.S in April 2024 (inpatient setting) and July 2024 (outpatient setting) and reflects the shipment of DefenCath to
direct customers and specialty distributors, net of estimates for applicable variable consideration.  Revenue from the Melinta Portfolio
represents $45.5 million of product sales, net of applicable variable consideration, for the post-acquisition period, starting August
29, 2025.

In 2024, we entered into multi-year
commercial supply agreements with a large and several mid-sized dialysis organizations. Each dialysis provider customized its implementation
plan to provide access to patients based on a variety of clinical and other factors. We believe the currently contracted customer base
represents roughly 60% of the outpatient dialysis centers in the U.S. in terms of the total addressable patient market. During the
second quarter of 2025, the Company’s largest volume customer commenced ordering, patient utilization commenced in the third quarter
of 2025, driving significant sales growth in the second half of 2025 relative to the first half. 

Contract revenue for 2025
is related solely to the acquired operations of Melinta after the Closing Date of August 29, 2025 and reflects $4.2 million earned under
the BARDA agreement and $3.2 million related to milestone, royalty, and inventory revenue under Melinta’s licensing agreements.

The following is a summary
of our Total Revenue between the DefenCath sales and the contribution from the Melinta Portfolio from the Closing Date of August 29, 2025
through the end of 2025. The table below represents consolidated revenue for the year ended December 31, 2025 and 2024 (in thousands):

2025

2024

Product Sales:

DefenCath

$

258,813

$

43,472

Melinta Portfolio

45,531

-

Total product sales

304,344

43,472

Contract Revenue

7,365

-

Total Revenue

$

311,709

$

43,472

Cost of Revenue. Cost
of revenue for the year ended December 31, 2025 was $22.1 million as compared to $3.0 million for the same period in 2024, an increase
of $19.1 million, or 628%. Cost of revenues include direct and indirect costs related to the manufacturing and distribution of DefenCath
and the Melinta Portfolio, including product cost, packaging services, freight, and an allocation of overhead costs that are primarily
fixed such as salaries, benefits and insurance. The increase from 2024 to 2025 is primarily driven by higher product sales and to a lesser
extent, costs associated with the sales of the Melinta Portfolio.

Intangible Asset Amortization.
Amortization of intangible assets was $13.9 million and $0.2 million for the year ended December 31, 2025 and 2024, respectively. The
increase was primarily due to the intangible assets acquired in connection with the Merger.

38

Research and Development
Expense. R&D expense for the year ended December 31, 2025 was $19.3 million, an increase of $15.4 million, or 390%, from $3.9
million for the same period in 2024. The increase was due primarily to the increases in personnel and clinical trial services in support
of the ongoing clinical studies initiated in the fourth quarter of 2024 as well as severance costs and the incremental cost of Melinta’s
operations starting on August 29, 2025.

Selling and Marketing Expense.
S&M expense was $38.1 million for the year ended December 31, 2025, an increase of $9.4 million, or 32%, from $28.7 million for the
same period in 2024. These increases were primarily due to severance costs and the incremental cost of Melinta’s operations starting
on August 29, 2025 and the termination cost associated with the Syneos contract, offset by additional marketing costs related to the pre-launch
and launch of DefenCath in 2024.

General and Administrative
Expense. G&A expense for year ended December 31, 2025 was $68.2 million, an increase of $38.2 million, or 128%, from $30.0 million
for the same period in 2024. These increases were primarily driven by the Merger-related transaction costs, severance costs, the incremental
cost of Melinta’s operations starting on August 29, 2025 including higher headcount with the combined company, non-cash charges
for stock-based compensation and an increase in costs related to business development.

Interest Income. Interest
income was $3.8 million for the year ended December 31, 2025 compared to $2.6 million for the same period last year, an increase of $1.2
million, or 49%, driven by higher average cash balances.

Unrealized Gains on Marketable
Security. Unrealized gain on marketable security represents the change in fair value for our marketable equity securities in Talphera,
a publicly-traded biotechnology company, from the date that the stock was acquired to December 31, 2025. Fair value is determined based
on the closing stock price of Talphera on the balance sheet date. For the year ended December 31, 2025, we recognized an unrealized gain
on marketable security of $5.4 million related to the increase in fair value of our Talphera stock.

Change in Contingent Consideration.
For the year ended December 31, 2025, we recognized a $6.5 million change in contingent consideration, primarily driven by the changes
in the present value of expected payments resulting from discount accretion and updates to the risk-free rate used in the initial Closing
Date valuation. As the Merger closed in 2025, there was no comparative amount in 2024.

Interest
Expense. Interest expense was $2.8 million for the year ended December 31, 2025 compared to $0.0 million for the same period last
year, an increase of $2.8 million. This was primarily driven by the interest expense and accretion related to the Notes.

Tax Benefit. The tax benefit for year ended December 31, 2025 was $13.0 million,
an increase of $11.6 million, or 835% from $1.4 million for the same period in 2024. As of December 31, 2025, the Company partially released
a valuation allowance primarily related to US Federal net operating losses (“NOLs”). The release of valuation allowance was
mainly attributed to the expected utilization of historical CorMedix federal NOLs. The Company will continue to evaluate the realizability
of its remaining deferred tax assets each reporting period and adjust the valuation allowance as appropriate based on changes in cumulative
results, forecasts of future taxable income, or other objective evidence as required by ASC 740-10-35. The tax benefit from the release
of the valuation allowance was partially offset by state taxes.

Other
Comprehensive (Loss) Income. Unrealized foreign exchange movements related to long-term intercompany loans, the translation
of the foreign affiliate financial statements to U.S. dollars and unrealized movements related to short-term investment are recorded
in other comprehensive (loss) income. The foreign entity was dissolved in 2025.

Liquidity and Capital Resources

Sources of Liquidity

We achieved profitability
for the year ended December 31, 2025, driven primarily by product sales of DefenCath. In addition, we received net proceeds of $7.8 million
from the issuance of 715,051 shares of common stock under our at-the-market-issuance sales agreement (“ATM program”), we raised
net proceeds of $144.3 million from the Notes offering in August 2025 and $82.4 million from the Follow-On Offering in June 2025. We may
continue to utilize external sources of cash to further fund operations. See Notes 7 and 10, respectively, to the Consolidated Financial
Statements for further details on the Notes, Follow-On Offering, and ATM program.

39

Net Cash Provided by (Used in) Operating
Activities

Net cash provided by operating
activities for the year ended December 31, 2025 was $175.0 million as compared to net cash used in operating activities of $50.6 million
for the same period in 2024. Net cash provided by operating activities was primarily attributable to the net income of $163.1 million
for the year ended December 31, 2025 compared to a net loss of $17.9 million in the comparison period in 2024.

Net Cash (Used in) Provided by Investing
Activities

Net cash used in investing
activities for year ended December 31, 2025 was $308.4 million as compared to $21.2 million of net cash provided by investing activities
for the same period in 2024. The net cash used during the year ended December 31, 2025, was mainly driven by the acquisition of Melinta.

Net Cash Provided by Financing Activities

Net cash provided by financing
activities for the year ended December 31, 2025 of $238.5 million was attributable to the Notes Offering in August 2025, the Follow-On
Offering in June 2025, and from our ATM program. Net cash provided by financing activities for the year ended December 31, 2024 was $26.3
million attributable to the net proceeds received from the sale of our common stock in our ATM program and stock option exercises.

Funding Requirements and Liquidity

Our total cash, cash equivalents
and short-term investments as of December 31, 2025, was $148.5 million, excluding restricted cash of $1.0 million, compared with $51.7
million as of December 31, 2024, excluding restricted cash of $0.1 million. As of December 31, 2025, $22.1 million of the Company’s
common stock remains available for potential sale under the ATM program. Additionally, we have $15.0 million of remaining capacity available
under our 2024 Shelf Registration Statement for the issuance of Company securities.

We expect to continue to fund
operations from cash collections of accounts receivable, our cash on hand, cash equivalents and short-term investments, and through potential
capital raising sources, which may be dilutive to existing stockholders. We may seek to sell additional equity or debt securities through
one or more discrete transactions, but can provide no assurances that any such financing will be available on acceptable terms, or at
all. Moreover, the incurrence of indebtedness would result in increased fixed obligations and could contain covenants that would restrict
our operations.

Our actual cash requirements
may vary materially from those now planned due to a number of factors, including any material change in commercial operations pertaining
to our Products or the focus and direction of our research and development programs, any acquisition or pursuit of development of new
product candidates, competitive and technical advances, the costs of commercializing any of our product candidates, and costs of filing,
prosecuting, defending and enforcing any patent claims and any other intellectual property rights.

We currently estimate that
as of December 31, 2025, we have sufficient cash, cash equivalents and short-term investments to fund operations for at least twelve months
from the issuance of these financial statements.

40

Contractual Obligations

We entered into a seven-year
operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922. The lease agreement,
with a monthly average cost of approximately $17,000, commenced on September 16, 2020 and has a term through October 2027.  

Following the Merger, the
Company now has operating leases for two additional offices; a lease agreement for our corporate headquarters at 389 Interpace Parkway,
Parsippany, New Jersey, which expires in March 2030, and a sublease agreement for an office facility in Lake Forest, Illinois, which expires
in September 2031. The total monthly expense associated with these leases is approximately $60,000.

In addition, following the
Merger, we have finance leases for numerous vehicles that are used by certain field-based employees The lease term for each vehicle is
between 48 to 60 months with an aggregate approximate monthly expense of $70,000.

In connection with the Merger,
we are required to make certain contingent payments to the former Melinta equity holders. Upon the issuance of the FDA marketing approval
of REZZAYO (or any product that contains the active ingredient rezafungin), for the prevention or prophylaxis of invasive fungal infections
in adult patients undergoing allogeneic stem cell blood and marrow transplant or the regulatory equivalent (the “REZZAYO Second
Indication”) on or prior to June 30, 2029, the Company shall pay, in cash or common shares, par value $0.001 per share, of the Company
at the Company’s election, to the former Melinta equity holders the following payments (the “REZZAYO Milestone”):

(i)

if the FDA-approved labeling includes candida, $20 million;

(ii)

if the FDA-approved labeling includes aspergillus, $2.5 million;
and

(iii)

if the FDA-approved labeling includes pneumocystis, $2.5 million.

Further, we are obligated
to pay to the former Melinta equity holders tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN U.S.
net sales.

In addition, in connection
with the Merger, we assumed certain commitments under the REZZAYO License Agreement that Melinta held with its licensor Mundipharma, including
a regulatory milestone of between $30 million and $40 million upon receipt of FDA approval for the REZZAYO Second Indication, a number
of commercial milestones upon exceeding certain net sales targets, and tiered net sales-based royalties. The REZZAYO License Agreement
additionally stipulates that upon the earlier of thirty-days following the receipt of the marketing approval for the prophylaxis indication
or on June 30, 2028, we will assume all rights, title and interest in and to all product filings for the current product in the U.S. 

In connection with the purchase
of the active pharmaceutical ingredient (API) for VABOMERE, we have committed to API deliveries from the CMO in 2026 with a total cost
of €5.9 million, subject to inflation adjustments.

In December 2024, the Company
entered into a three-year agreement with Syneos Health Commercial Services, LLC (“Syneos”) under which Syneos agreed to provide
a dedicated inpatient field sales force to exclusively promote DefenCath to hospitals and health systems. The Company paid an up-front
implementation fee and was obligated to pay a fixed monthly fee.  The Company signed a termination agreement, effective October 1,
2025 whereas the related services to CorMedix were completed on December 31, 2025.  As of December 31, 2025, the Company has a total
net obligation of $2.3 million, consisting of $1.3 million of accrued termination fees and $1.6 million of unpaid expenses incurred through
December 31, 2025, which will be partially offset by a security deposit of $0.6 million. We expect complete settlement to occur during
the first quarter of 2026.

41

Critical Accounting Estimates

We prepare our consolidated
financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates
that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates,
as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences
between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates
on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations
for the future based on available information. We evaluate these estimates on an ongoing basis. We consider an accounting estimate to
be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting
estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates
that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.
Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of
Directors. In addition, there are other items within our financial statements that require estimation, but are not deemed critical as
defined above. Changes in estimates used in these and other items could have a material impact on our financial statements.

●

Litigation contingencies are assessed and judgments are made to determine if an unfavorable outcome is considered probable or reasonably possible, and when considered reasonably possible but not probable, the contingency is disclosed along with an estimate of the possible loss or range of loss. If a liability is possible or probable, but no reasonable estimation of loss can be made, we will disclose the nature of the contingency and state that such an estimate cannot be made. Such estimates and judgements are based on information obtained through the discovery process, court filings and follow on filings by the plaintiffs as well as the stage of litigation.

●

We account for product revenue from the sale of our Products in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”), which entails our estimates and judgments primarily in determining the transaction price and more specifically as it relates to variable consideration associated with the contracts. Our customers are primarily located in the United States and consist primarily of outpatient service providers and to a lesser extent specialty wholesale distributors. Variable consideration pertaining to an allowance for product returns of short-dated or expired product requires estimation as our customers may have differing utilization, storage and distribution methods and we do not yet have significant historical trends specific to DefenCath. The Company’s product return accrual takes into consideration estimates of product held by its customers, the distribution channel, the shelf life of the product held by customers, as well as when the product is eligible for return based on our returns good policy. We have established the estimate for returns based on specific customer circumstances, industry best practices and management experiences, which will continuously be refined as new information is received. At December 31, 2025, we had $18.3 million in accrued returns allowance, including the balance recorded for the Melinta Portfolio.

Variable consideration pertaining to
accrued Medicaid rebates requires estimation as our customers may have differing utilizations rates of Medicaid coverage, different utilization
within States which may be in either the primary or secondary positions, together with as well as general fluctuations in patient populations
over time. Based on the relatively short time since product launch of DefenCath and the inherent lag time in states’ Medicaid processing,
the utilization of information the Company has received is limited and, as such, there is a lack of significant historical trends for
Medicaid utilization. The Company’s accrual does take into consideration its customers’ recent actual Medicaid utilization
rates as well as anticipated Medicaid utilization rates. At December 31, 2025, the Company had $12.4 million in accrued Medicaid rebates,
including the balance recorded for the Melinta Portfolio.

During the year ended December 31,
2025, a change in estimate was recorded for variable consideration pertaining to Medicaid rebates, specific to DefenCath. During the three
months ended June 30, 2025, new information was obtained by the Company surrounding Medicaid utilization rates for certain states that
reimburse service providers using DefenCath. The resulting change in accounting estimate negatively impacted net sales, income from continuing
operations and net income for the year ended December 31, 2025. The resulting change in estimate negatively impacts full year 2025 revenue,
continuing operations and net income in the amount of $1.7 million. This impacted basic and diluted earnings per share by $0.02 and $0.02
per share, which would have caused earnings per share and diluted earnings per share to be $2.27 and $2.06 respectively. , with a corresponding net income of $164.7 million.

42

●

As of September 30, 2025, the Company had achieved cumulative pre-tax income over the most recent three-year period, and therefore, in accordance with ASC 740, Income Taxes, management evaluated both positive and negative evidence in assessing the realizability of its deferred tax assets. In addition to the historical earnings, the Company considered factors such as the sustainability of current revenue sources, excluding potential future revenue from additional indications of our Products currently under development, and future net income projections. Based on this evidence, the Company concluded that is more-likely-than-not (as defined in ASC 740-10-30-5(e)) that it will realize the benefit of certain deferred tax assets, related primarily to utilization of its U.S. federal NOL carryforwards, within the applicable carryforward periods provided under Internal Revenue Code (“IRC”) Section 172.

As a result of this conclusion,
the Company partially released its valuation allowance previously recorded against its deferred tax assets, recognizing an income
tax benefit of $61.5 million for the year ended, December 31, 2025. The release of valuation allowance was mainly attributed to the
expected utilization of historical CorMedix federal NOLs. The Company will continue to evaluate the realizability of its remaining
deferred tax assets each reporting period and adjust the valuation allowance as appropriate based on changes in cumulative results,
forecasts of future taxable income, or other objective evidence as required by ASC 740-10-35.

●

We account for acquired businesses using the acquisition method of accounting under Business Combinations (Topic 805). With respect to business combinations, we determine the purchase price, including contingent consideration, and allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed, based on estimated fair values. The excess of the purchase price over the identifiable assets acquired and liabilities assumed is recorded as goodwill.

We engaged a third-party professional
service provider to assist us in determining the fair values of the purchase consideration, assets acquired, and liabilities assumed.
Such valuations require management to make significant estimates and assumptions, especially with respect to contingent liabilities associated
with the purchase price and intangible assets, such as developed product rights and in-process research and development programs. Critical
estimates that we have used in valuing these elements include, but are not limited to, future expected cash flows using valuation techniques
(i.e., Monte Carlo simulation models) and discount rates. Management’s estimates of fair value are based upon assumptions believed
to be reasonable, but which are inherently uncertain and unpredictable.

We record the different elements of contingent consideration resulting from a business combination at their respective fair values on the acquisition date. The purchase price of Melinta included contingent consideration related to certain tiered royalty payments based on future net sales, as well as to regulatory milestones associated with the acquired products. Over time, increases in fair value from the passage of time are accreted and recorded as non-cash interest expense in the consolidated statements of operation.

Changes to contingent consideration obligations, other than the passage of time, may result from adjustments related, but not limited, to changes in discount rates and the number of remaining periods to which the discount rate is applied, updates in the assumed achievement or timing of any regulatory milestone or changes in the probability of certain clinical events, changes in our forecasted sales of products acquired, and changes in the assumed probability associated with regulatory approval. At the end of each reporting period, we evaluate the need to remeasure the contingent consideration and, if appropriate, we revalue these obligations and record increases or decreases in their fair value in selling, general and administrative expenses within the accompanying consolidated statements of operations.

Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, any change in the assumptions described above, could have a material impact on the amount we may be obligated to pay as well as the results of our consolidated results of operations in any given reporting period.